Deramciklan (EGIS-3886) je lek koji deluje kao antagonist na 5-HT2A receptoru,[3] kao inverzni agonist na 5-HT2C receptoru,[4] i kao inhibitor GABA preuzimanja.[5]
Deramciklan
|
(IUPAC) ime
|
N,N-dimetil-2-([(1R,4R,6S)-1,7,7-trimetil-6-fenil-6-biciklo[2.2.1]heptanil]oksi)etanamin
|
Klinički podaci
|
Identifikatori
|
CAS broj
|
120444-72-6
|
ATC kod
|
nije dodeljen
|
PubChem[1][2]
|
119590
|
UNII
|
O5KFK61E74 Y
|
Hemijski podaci
|
Formula
|
C20H31NO
|
Mol. masa
|
301,466 g/mol
|
SMILES
|
eMolekuli & PubHem
|
InChI |
InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1 Y Key: QOBGWWQAMAPULA-RLLQIKCJSA-N Y |
|
Farmakoinformacioni podaci
|
Trudnoća
|
?
|
Pravni status
|
|
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Kanerva, H.; Vilkman, H.; Någren, K.; Kilkku, O.; Kuoppamäki, M.; Syvälahti, E.; Hietala, J. (1999). „Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study”. Psychopharmacology 145 (1): 76–81. DOI:10.1007/s002130051034. PMID 10445375.
- ↑ Pälvimäki, E. P.; Majasuo, H.; Kuoppamäki, M.; Männistö, P. T.; Syvälahti, E.; Hietala, J. (1998). „Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation”. Psychopharmacology 136 (2): 99–104. DOI:10.1007/s002130050544. PMID 9551765.
- ↑ Kovács, I.; Maksay, G.; Simonyi, M. (1989). „Inhibition of high-affinity synaptosomal uptake of gamma-aminobutyric acid by a bicyclo-heptane derivative”. Arzneimittel-Forschung 39 (3): 295–297. PMID 2502985.